Skip to Content


National Cancer Institute; Notice of Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Director's Consumer Liaison Group.

Date: October 20-22, 2009.

Time: October 20, 2009, 2 p.m. to 6 p.m.

Agenda: Welcome, Overview of the NCI Advanced Therapeutics Platform, Expert Panel on NCI Therapeutics Platform.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

Time: October 21, 2009, 8:30 a.m. to 5:30 p.m.

Agenda: Gaining Community Input on NCI Therapeutics Platform, Communicating with the Community About the NCI Therapeutics Platform, Advocates in Research Working Group Discussion, NCI National Outreach Network Discussion.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

Time: October 22, 2009, 8:30 a.m. to 1 p.m.

Agenda: Communicating with the Community about the NCI Therapeutics Platform (cont'd), Engaging the Community Around the NCI Therapeutics Platform, Discussion with NCI Director.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Benjamin Carollo, MPA, Advocacy Relations Manager, Office of Advocacy Relations, Building 31, Room 10A30, 31 Center Drive, MSC 2580, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892-2580. 301-496-0307.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page:​advisory/​dclg/​dclg.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Start Signature

Dated: August 17, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. E9-20170 Filed 8-20-09; 8:45 am]